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Interleukin 2-induced increase of vascular permeability without decrease
of the intravascular albumin pool
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Sumnmry Interleukin 2 (IL-2) exhibits anti-tumour activity. High-dose IL-2 regimens are limited by side-
effects such as pulmonary oedema and a systemic vascular leak. The mechanisms by which IL-2 mediates
transvascular fluid and protein losses in humans are largely unknown. We have, therefore, measured the
transcapillary escape rate (TER) of albumin as a reflection of the vascular permeability by injecting
[1WI]albumin (5 glCi i.v.). In ten melanoma patients pretreated with interferon alpha (IFN-a) TER of albumin
was measured before and after IL-2 injections (1.5 x 106 Cetus-U. s.c. daily for 4 days). The TER of albumin
increased from 9.4 ± 2.7% h-1 before to 14.9 ± 3.3% h-' (P<0.001) after IL-2 injections and the absolute
outflux of albulmin (J.1b) from 159 ± 28 mg kg-' h 'to 261 ± 44mg kg -' h -' (P<0.001), whereas the int-
ravascular albumin pool remained stable (136 ± 19 g vs 136 ± 18 g). IL-2 and IL-6 were not detectable in the
plasma prior to IL-2 injections and increased to 549±315Uml-' (P<0.001) and 7±6pgml[' (P<0.01),
respectively, after IL-2 administration. In conclusion, IL-2 increases the vascular permeability in humans,
without affecting the intravascular albumin pool. This suggests that mechanisms such as the lymphatic return
can compensate for the severe transendothelial fluid/albumin losses.
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Interleukin 2 (IL-2). a T-cell-derived lymphokine, activates
non-specific cytotoxic lymphocytes, which are capable of lys-
ing tumour cells without exerting lytic activity against normal
cells (Grimm et al.. 1982). On the basis of this anti-tumour
effect, IL-2 alone or in combination with other cytokines or
chemotherapeutic agents is used as a treatment in advanced
cancer or as an adjuvant immunotherapy (Rosenberg et al.,
1987; Paciucci, 1992; Vlasveld et al., 1992). The anti-tumour
activities of IL-2 are dose and schedule related, as shown in
various clinical studies (Rosenberg et al., 1989) and in experi-
mental animals (Rosenberg et al., 1985). However, high-dose
IL-2 regimens are limited by substantial toxicity, in particular
pulmonary and systemic oedema, decreased systemic resist-
ance, increased cardiac output, hypotension and oliguria
mimicking a septic shock-like condition (Lotze et al., 1986;
Parkinson, 1988).
Intravenous injection of IL-2 induces extravasation of
labelled albumin in experimental animals (Rosenstein et al.,
1986; Harms et al., 1989). However, the exact mechanisms by
which IL-2 mediates the increase in vascular permeability are
largely unknown. Some authors have demonstrated a direct
effect of IL-2 in vitro on vascular permeability (Fairman et
al., 1987; Downie et al., 1992), whereas others have suggested
that IL-2 exerts this effect by induction of various cytokines
(Mier et al.. 1988; Fraker et al., 1989; Edwards et al., 1992)
such as tumour necrosis factor alpha (TNF-m) or interferon
gamma (IFN-y).
So far the in vivo effects of IL-2 administration on vascular
permeability have been studied mainly in animals. In the
present study, we have measured the transcapillary escape
rate (TER) of albumin as a reflection of the vascular
permeability in patients receiving IFN-a and IL-2 as an
adjuvant treatment for malignant melanoma. Furthermore,
we have investigated the changes in plasma concentrations of
the IL-2-inducible cytokines and the acute-phase proteins
after IL-2 injections. The aim of the study was to determine:
(1) if IL-2 administration induces the expected increase in
TER of albumin, and if this increase would accompany a
decrease in plasma albumin and (2) if. thus, IL-2 might be a
major regulatory factor of increased vascular permeability in
humans.
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Materals and methods
Patients
Ten patients (one woman, nine men, mean age 53 + 12, range
26-64 years) with malignant melanoma were studied. All
patients were regarded as tumour free after prior surgery,
which took place at least 4 weeks before the study. They
were treated with recombinant human IFN-a (Intron A,
Essex Chemie, Lucerne, Switzerland) and IL-2 (Proleukin,
EuroCetus, Amsterdam, The Netherlands) as an adjuvant
treatment in a multicentre trial at the Department of Derma-
tology, University of Zunrch, Switzerland. After pretreatment
with IFN-x for 5 weeks (3 x 106 IU s.c. three times per week
for 4 weeks and 3 x 106 IU s.c. daily for the last week) the
patients were admitted to hospital for the IL-2 injections
(1.5 x 106 Cetus-U. s.c. daily for 4 days).
The transcapillary escape rate of [1251]albumin was
measured immediately before the first IL-2 injection and 6 h
after the second IL-2 injection.
Written informed consent was obtained from the patients
before entering the study. The study protocol was approved
by the ethical committee of the University Hospital of
Zurich.
Exclusion criteria consisted of iodine intolerance, thyroid
disease, nephrotic syndrome, diabetes mellitus and cirrhosis
of the liver.
Determination ofthe transcapillarv escape rate of
['-5I]albunin
All patients received 60 mg of potassium iodide orally prior
to the first injection of ['"Ilalbumin and for 14 days
thereafter, in order to block ['5I]uptake by the thyroid gland.
The TER of ['5Ialbumin was measured as described
previously (Ballmer et al., 1992, 1994). After securing
baseline blood samples 5 ACi of ["'5Ilalbumin (Sari-125-A-2,
Sorin Biomedica, Saluggia, Italy) was injected intravenously
and blood samples were drawn at 10 min intervals up to
60 min from the opposite cubital vein. Radioactivity was
counted in duplicate 2 ml plasma samples in a gamma-
counter (Packard, Autogamma Analyzer, Canberra Indust-
nes, Meriden, CT, USA). Radioactivity was expressed as
counts per mn (c.p.m.) and the counts were plotted against
time. TER was determined from the linear regression line ofI lo lWd 2 _s_ v w pm esablity
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the decrease in plasma radioactivity over 60 min and ex-
pressed in per cent per hour (% h-'). Plasma volume was
calculated as the ratio of the injected radioactivity and the
counts in plasma at time zero obtained by extrapolation of
the counts-time curve to the ordinate. The product of
plasma albumin times plasma volume equals the intravas-
cular albumin mass (IAM). J.4b, i.e. the absolute albumin
outflux, is the product of TER and LAM, expressed as mg
per kg body weight per hour (mg kg' h-').
Plasmna protein concentrations
'Negative' (i.e. normally decreasing in the acute-phase
reaction) acute phase proteins, i.e. albumin, prealbumin and
transferrin, and 'positive' (i.e. normally increasing in the
acute-phase reaction) acute-phase proteins, i.e. C-reactive
protein (CRP) and fibrinogen, were also measured before the
first and 6 h after the second IL-2 administration. CRP was
determined by turbidimetry (Boehringer, Mannheim,
Germany) on a Hitachi autoanalyser (BM 717), transferrin
by spectrophotometry (Uni-Kit, Roche, Switzerland), pre-
albumin by nephelometry (Behring, Marburg, Germany) and
albumin with bromcresol green (Doumas et al., 1971).
Fibrinogen was analysed according to the method of Clauss
(1957), and blood sedimentation rate according to Wester-
gren. (International Committee for Standardization in
Hematology, 1973).
Cytokine plasma concentrations
Cytokine plasma concentrations were measured at the same
time points as above using for each cytokine a commercially
available enzyme immunoassay (IL-2 and IL-6, Research and
Diagnostic Systems, Minneapolis MN, USA; TNF-a, Endo-
gen, Boston MA, USA; IFN-y, Life Tech Basle, Switzerland;
and IFN-a, Anawa Laboratonen, Wangen, Switzerland).
79
Statistics
Data are presented as means ± standard deviation (x ± SD).
Statistical comparisons were done using the paired Student's
t-test, assuming a significance level of .0.05.
Results
One patient was treated for hypertension with an angio-
tensin-converting enzyme inhibitor, and two suffered from a
chronic polyarthritis, which was not active at the time of the
investigation. During the study time no other concomitant
disease occurred. Four patients took paracetamol
(2 x 500mg) after the IL-2 injection. Body temperature,
measured immediately before ['VIJalbumin injections, rose
from 36.3 ± 0.4C to 37.0 ± 0.7C (P<0.01) after IL-2
administration. Body weight did not change under IL-2
administration. In Table I the characteristics of the patients
are summarised. Eight patients suffered from superficial
spreading melanoma (Clark level HII-IV, Breslow level
0.9-3.3 mm), one from nodular melanoma (Clark IV, Bres-
low 1.95 mm) and one from conjunctival melanoma. Four
patients had locoregional lymph node metastases and one
had satellite metastases. All patients were surgically treated in
a curative way and were regarded as tumour free when they
entered the study protocol. Table II summarises the values of
plasma albumin concentrations, IAM, TER and J4b. Plasma
albumin concentration decreased from 46 ± 1 g 1' before to
43±3gl-1 after IL-2 treatment (P=0.01), whereas IAM,
the intravascular albumin mass, remained stable (136 ± 18 g
before vs 136 ± 18 g after IL-2 administration) as a result of
a slight increase in plasma volume (2987 ± 452 ml and
3163 ± 477 ml respectively, P<0.05). TER and the absolute
albumin outflux (J4b) showed a marked elevation from
9.4 ± 2.7% h-' to 14.9 ± 3.3% h-' (P<0.001) and from
Table I Climncal charactenrstics
Stage
Patient Age Histology Breslow (mm) Clark Metastases
1 57 NM 1.9 IV None
2 26 SSM 2.4 IV None
3 54 NM 1.95 IV None
4 60 SSM 0.7 III Satellites
5 63 SSM 2.4 IV None
6 64 SSM 1.1 IV Locoregional LN
7 61 SSM 1.3 IV None
8 45 SSM 0.8 III Locoregional LN
9 62 CM - - Locoregional LN
10 42 SSM 3.3 IV Locoregional LN
SSM, superficial spreading melanona; NM, nodular melanoma; CM, conjunctival
melanoma; LN, lymph nodes.
Table I Plasma albumin concentration (PA), intravascular albumin mass (LAM), transcapillary
escape rate of albumin (TER) and absolute albumin outflux (J.b) before and after IL-2
administration
PA (gt-1) IAM (g) TER (% h-1) Jff, (mgkg->h-')
Patient Before After Before After Before After Before After
1 45 40 141 136 6.4 13.0 110 215
2 48 47 120 133 7.8 12.9 155 284
3 46 45 141 163 7.5 13.4 135 280
4 46 40 151 131 14.1 21.0 175 260
5 44 44 110 111 11.2 18.6 175 295
6 45 42 138 129 7.3 11.8 137 207
7 47 46 131 139 10.1 13.5 141 201
8 47 43 120 112 11.9 15.1 199 235
9 44 40 176 165 6.3 11.3 174 302
10 45 46 135 145 11.5 18.3 191 327
Mean 46 43* 136 136 9.4 14.9** 159 261**
s.d. 1 3 19 18 2.7 3.3 28 44
*P <0.01; **P <0.001.BK Ba*-Webe e i
159±28mgh-'kg-' to 261±44mgkg-'lh- r vely
(Figure 1).
Table IIl summarises the IL-2-induced changes in the
plasma concentrations of'negative' and 'positive' acute-phase
proteins. Transferrin significantly decreased from
32.2 ± 2.5 g1` to 29.6 ± 4.1 g1` (P<0.05), and prealbumin
from 372 ±64 mg 1` to 347 ±49mgI` without reaching
statistical significance (P = 0.067). In contrast, CRP rose
significantly from 2.0 ±2.4mgI` to 13.8 ±11.8 mgI`
(P<0.01), whereas fibrinogen moderately increased
(2.8 ±0.5 gI` before vs 3.2 ±0.5 g1` after IL-2 administra-
tion, P= 0.09) and blood sedimentation rate (BSR) ained
unchanged (see Table Ill).
Cytokine plasma concentrations are summarised in Table
IV. IL-2 plasma concentrations were not detectable before
treatment and inreased to 549 ± 315 UmlP' (P<0.001) 6h
after the second IL-2 adminisation. The IL-2-inducible
cytokines IFN-y and TNF-a did not show a consistent re-
sponse to IL-2 injections. IFN-y was not measurable in six
patients before and after treatment In two patients it in-
creased from 0 to 9 Uml-I and from 0 to 13 U mlr-, and in
another patient it dropped from 32 U ml1- to 0. TNF-a was
not detectable before IL-2 adminitation in seven patients.
After treatment it showed slightly elevated concentrations in
five patients and ained nged in two patients. In
three patients TNF-a was initially elevated and decreased
under theapy.
IL-6, however, was not detectable in all ten patients before
treatment, but increased in seven patients to 7±6 pg ml1
(P<0.01, range 5.3-16.5pgmml-) after 1L-2 adminisation.
After discontinuing IFN-a therapy I day before admission,
baseli values were initially elevated (22 + 18 IUml-') and
fell 24h later to 14±27IUml-' (P=0.26).
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Fugwe 1 Transcapillary escape rate (TER) and absolute albumin
outlfux (Jab) before and after subcutaneo IL-2 injcions.
Table m Plasma concentrations of 'negaive' and 'positive' acute
phase proteins before and after IL-2 administration
Before IL-2 After IL-2
Prealbumin (mg I) 372 ± 64 347 ± 49
Transferrin (mg I') 32.2 ± 2.5 29.6± 4.1*
CRP (mg 1) 2.0 ± 2.4 13.8 ± 1.8**
Fibrinogen (g l-1) 2.8 ± 0.5 3.2 ± 0.5
BSRb (mm h-') 13.6 ± 6.3 13.6 ±7.2
*P <0.05; **P <0.01. 'CRP, C-reactive protein. BSR, blood
sedimentation rate.
Tabe IV Plasma cytokine concentrations before and after IL-2
administration
Before IL-2 After IL-2
IL-2 (Uml-,) 0 549 315**
IL-6 (pgml ') 0 7±6*
ThNF- (pg ml) 29 64 10 21
IFN-7 (U ml ') 4 10 4 7
IFN-a (Uml-') 22 18 14 27
*P <0.01; **P<0.001.
An increase in vascular permeability causing pulmonary and
systemic oedema is a common side-effect of immunotherapy
with IL-2 (Lotze et al., 1986; Rosenberg et al., 1987). How-
ever, the effects of IL-2 adminisration on transmembranous
fluid and protei shifts have, so far, mostly been vestigated
in vitro, e.g. in cell culture systems (Downie et al., 1992), or
in experimental animals (Rosenstein et al., 1986; Edwards et
al., 1991), whereas human data are missing. We have, there-
fore, investigated the effects of subcutaneous injections of
human recombinant IL-2 on vascular permeability in patients
undergoing adjuvant immunotherapy with IL-2 for malignant
melanoma. As a reflection of the vascular permeability, we
have measured the transcapilary escape rate of ["I1jalbumin
(Fleck et al., 1985; Ballmer et al., 1992, 1994). TER is an
estimate of the albumi losses across the vascular endo-
thelium, and can reliably be measured by intravenous injec-
tion of labelled albumin (Parving, 1973; Rossing et al., 1976;
Fleck et al., 1985; Ballmer et al., 1992, 1994). In healthy
human subjects TER is approximately 4-7% per hour, i.e.
120% of the intravascular albumin pool escapes per day with
subsequent redistribution.
In many pathological conditions, in paricular in most
inflammatory , TER can markedly increase. Thus, we
reported a substantial increase in TER in patients suffering
from acute infectious disease (Balmer et al., 1994). Fleck et
al. (1985) showed a 2-fold elevation of TER within a few
hours after a surgical trauma. The exact mechanism, how-
ever, regulating the vascular permeability is largely unknown.
In the present study, TER and Jwb (the absolute outflux of
labeled albumin) increased by roughly 60% after IL-2 injec-
tions, and, simultaneously, plasma albumin concentration
slightly decreased, whereas plasma volume correspondingly
increased. Thus, the intravascular albumin mass, i.e. the
product of plasma albumin concentration and plasma
volume, was unaffected by the increase in TER/Jwb. This was
not entirely unexpected, since in an earlier study on the
impact of acute inflammatory diseases on TER (Ballmer et
al., 1994) we had already observed a slightly positive (instead
of the expected negative) correlation between TER and
plasma albumin concentrations. Apparently, the massive in-
crease in TER/Jab produced by IL-2 injections can be com-
pensated for. We hypothesise that (a) direct redistribution of
albumin back to the intravascular space occurred and (b) the
lymphatic system retured a substantial amount of the acces-
sory albumin/fluid that had escaped as a result of the in-
crease in vascular permeability. Physiologically, the lym-
phatic system returns the entire plasma protein pool per day
to the intravascular space (Granger, 1970). Under in-
flammatory conditions, the lymphatic system can increase its
transport capacity several times (Granger, 1970; Balhmer et
al., 1994). An overload of this transport capacity leads to
clinically manifest oedema formation. In our patients, how-
ever, no signs of fluid retention, i.e. oedema or gain in body
weight, occurred, thus supporting the hypothesis that direct
redistribution and/or lymphatic return was potent enough to
compensate for the increase in TER and Ja. The fact, that
the lymphatic return might be an important mechanism to
compensate for the increase in TER is supported by a recent
study, in which an IL-2-induced increase in lymphatic flow
and in tansvascular fluid and protein filtration was shown in
experimental animals (Harms et al., 1989).
The present study was also an attempt to identify whether
IL-2 administration has any direct effects on vascular
permeability in humans. In various in vivo and animal studies
IL-2 was shown to be an important pathogenetic factor
affecting vascular permeability. Thus, Harms et al. (1989)
demonstrated an IL-2-induced increase in pulmonary fluid
and protein permeabiity in sheep, and Downie et al. (1992)
found a direct in vitro stimulatory effect of IL-2 on albumin
permeability in human and bovine endothelium. In contrast,
Edwards et al. (1992) suggested that IL-2 is not a direct
stimulatory factor for vascular permeability: when IL-2 was
given together with anti-TNF-a antibody, the albumin extra-bIni.rlsd. 2 cicri wsesw permeabIlty
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vasation was clearly reduced. However, in line with two
recent studies in humans (Michie et al., 1988; Economou et
al., 1991), we have not found consistently elevated plasma
TNF-c concentrations after IL-2 injections. Moreover, direct
TNF-a administration was unable to induce an increase in
vascular permeability of albumin and lung wet weights in
experimental animals (Puri, 1989), suggesting that TNF-x is
unlikely to be the most relevant IL-2-induced direct mediator
affecting albumin permeability.
Interestingly, interleukin 6 plasma concentrations were
elevated in seven out of ten patients after IL-2 injections in
the present study. Although IL-6 has, so far, not been con-
sidered to be an important regulatory factor for capillary
permeability, Maruo et al. (1992) demonstrated that IL-6
increased the passage of labelled albumin across an endo-
thelial monolayer in vitro. The fact that IL-6 plasma concen-
trations were not elevated in three patients in the present
study, although plasma concentrations of the IL--stimulated
C-reactive protein (Baumann, 1990) were significantly ele-
vated after IL-2 injections, might indicate that we missed the
peak plasma concentration of IL-6 secretion after sub-
cutaneous IL-2 administration. In fact, there have been
hardly any reports regarding temporal changes in IL-6
plasma concentrations after subcutaneously injected IL-2. In
preliminary experiments, however, we found flu-like symp-
toms in all patients roughly 5-7 h after IL-2 injections and
therefore chose a 6 h time interval between IL-2 injections
and measurements of TER and cytokine plasma concentra-
tions in the present study. In fact, when IL-6 plasma concen-
trations were measured in two of these three patients 3 h
after IL-2 injections during the subsequent hospitalisation,
we found elevated values (42pgml-' and 5pgml-'). How-
ever, it remains unclear if the observed increase ofcirculating
IL-6 had any effect on the vascular permeability in the
present study.
The patients in the present study were already receiving
treatment with IFN-a when they were admitted to hospital
for IL-2 injections. When compared with our own results in
healthy volunteers (Ballmer et al., 1992, 1993, 1994) and
those in the literature (Fleck et al., 1985), the TER was
slightly higher before IL-2 injections than normal. Although
we cannot rule out a certain stimulatory effect of IFN-a, this
is not very likely, since IFN-a administration was discon-
tinued before IL-2 injections. Furthermore, we cannot exc-
lude the possibility that IFN-a primed the patients' suscep-
tibility towards the IL-2-induced increase in the vascular
permeability. In line with this, IFN-a given with IL-2 had a
synergistic effect on the vascular leak in the lungs of experi-
mental animals (Siegel et al., 1991).
In conclusion, subcutaneous IL-2 injection induced a
marked elevation in TER/J,% in melanoma patients, but this
had no effect on the intravascular albumin mass, suggesting
that compensatory mechanisms, such as the lymphatic return,
are powerful enough to equilibrate for fluid/protein extra-
vasation. Although IL-2 might have some direct stimulatory
effects on vascular permeability in humans, a direct effect of
IL-2 could only be verified by simultaneous administration of
antibodies against the IL-2-inducible cytokines. The admini-
stration of such antibodies in patients with malignant
melanoma, however, might abrogate anti-tumoral effects of
IL-2.
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